CSI 2021: Antiplatelet Therapy |
News and Updates
eMediNexus Coverage from: 
CSI 2021: Antiplatelet Therapy
Prof Robert Storey Sheffield, UK,  17 January 2022
Coronavirus Live Count Map India

remove_red_eye 2293 Views
COVID-19 Vaccine Updates


#Multispeciality

1 Read Comments                

Long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduces ischemic events with evidence of CV mortality reduction in those with highest ischemic risk who don’t have conditions associated with high bleeding risk (including anemia and prior hospitalization for bleeding).De-escalation to ticagrelor monotherapy at 3 months post-PCI appears to be a good option if long-term ischemic and stent thrombosis risk is low or there is ongoing bleeding/high risk ofbleeding.Clopidogre...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now